OBJECTIVES: Among the bone-targeted agents (BTAs) currently approved for the prevention of skeletal-related events (SREs), several characteristics may be considered by physicians when making treatment decisions. This study evaluated US physicians’ treatment preferences for preventing SREs in patients with bone metastases from solid tumors. METHODS: Physicians treating patients with bone metastases completed a web-enabled discrete-choice experiment survey consisting of 10 choices between pairs of hypothetical medication and patient profiles. Each profile included six medication attributes within a pre-defined range (primarily based on prescribing information and real-world practice): months until first SRE (10, 18 and 28 months); months until worsening of pain (3, 6 and 10 months); annual risk of osteonecrosis of the jaw (ONJ; 0%, 1% and 5%); annual risk of renal impairment (0%, 4% and 10%); mode of administration (subcutaneous injection, 15-minute infusion and 120-minute infusion every 4 weeks); and out-of-pocket cost to patients ($25, $75, $150 and $330). Choice questions were based on an experimental design with known statistical properties. The survey was pretested with 8 physicians using open-ended interviews. A main-effects random parameters logit model was estimated. RESULTS: A total of 200 US physicians completed the survey. Among the attribute levels included, out-of-pocket cost to patients, months until first SRE and the risk of renal impairment were the most important attributes. For those attributes, better levels (outcomes) were significantly preferred to worse levels (P